Prosigna Breast Test for Patients

The Prosigna Breast Risk of Recurrence test provides information about the chance your cancer can come back in the next 10-years if you were to have endocrine (anti-hormone) therapy alone. This along with the Risk of Recurrence (ROR) score may guide the decision to add chemotherapy to your treatment plan and reduce the chance of your cancer coming back.

The Prosigna Breast Risk of Recurrence test provides valuable information to help doctors and their patients with breast cancer make more informed and confident personalized treatment decisions. The test is indicated for patients with early-stage breast cancer that are hormone-receptor positive (HR+) prior to any non-surgical treatments.

PAM50 is the well-known and established 50-gene classifier that divides breast cancer into four intrinsic subtypes: Luminal A, Luminal B, HER2-enriched, and Basal-like. Each subtype is associated with distinct biological behaviors and responses to treatment. A core component of the Prosigna Breast Risk of Recurrence test is the gene expression analysis of the subtypes combined with clinical pathological information (tumor size, nodal status, proliferation score). This combination provides an accurate, reliable ROR score, 10-year probability of distant recurrence, and prediction of chemotherapy benefit.

The Prosigna Breast Risk of Recurrence test provides more comprehensive information than traditional testing approaches and more accurate ROR (Risk of Recurrence) information than other similar tests. It is the only breast cancer test based on the PAM50 genomic classifier that is used to determine the intrinsic subtype and enable a more accurate assessment of tumor gene expression patterns.

Only the Prosigna Breast Risk of Recurrence test considers the standard tumor information along with the intrinsic subtype and proliferation score in a single test.

The Prosigna Breast Risk of Recurrence test report contains results and relevant, interpretive information specific to each patient, enabling clinicians to provide a personalized and precise treatment plan.

The Prosigna Breast Risk of Recurrence test reports include key pieces of information:

• Risk of Recurrence (ROR) Score
• 10-year probability of distance recurrence (with 5 years of endocrine therapy)
• Chemotherapy benefit prediction
• Intrinsic Subtype (Luminal A, Luminal B, HER2-enriched, Basal-like)
• Proliferation score